Cost Effectiveness of Nonstatin-to-Statin Therapy

(1) report that adding ezetimibe or PCSK9 monoclonal antibodies to maximally tolerated statin therapy may be cost effective in high-risk and very high-risk patients, depending on baseline low-density lipoprotein cholesterol (LDL-C) levels. References 1 J.G. Robinson, R. Huijgen, K. Ray, J. Persons,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2017-04, Vol.69 (15), p.1995-1995
Main Author: Koh, Kwang Kon, MD, PhD
Format: Article
Language:English
Subjects:
Acute coronary syndromes
Adiponectin
Anticholesteremic Agents
Blood pressure
Cardiology
Cardiovascular
Cardiovascular disease
Cardiovascular diseases
Cardiovascular system
Cholesterol
Confidence intervals
Cost effectiveness
Cost-Benefit Analysis
Diabetes
Diabetes mellitus
Disorders
Fatty liver
Health risks
Heart diseases
Homeostasis
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia
Incidence
Insulin
Insulin resistance
Internal Medicine
Liver
Low density lipoprotein
Metabolic disorders
Metabolism
Monoclonal antibodies
Patients
Reductase
Risk groups
Risk management
Sensitivity
Side effects
Simvastatin
Statins
Steatosis
Studies
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:(1) report that adding ezetimibe or PCSK9 monoclonal antibodies to maximally tolerated statin therapy may be cost effective in high-risk and very high-risk patients, depending on baseline low-density lipoprotein cholesterol (LDL-C) levels. References 1 J.G. Robinson, R. Huijgen, K. Ray, J. Persons, J.J. Kastelein, M.J. Pencina, Determining when to add nonstatin therapy: a quantitative approach, J Am Coll Cardiol, Vol. 68, 2016, 2412-2421 2 S.J. Nicholls, R. Puri, T. Anderson, Effect of evolocumab on progression...
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2016.12.045